George J. Hutton

1.5k total citations
46 papers, 865 citations indexed

About

George J. Hutton is a scholar working on Pathology and Forensic Medicine, Neurology and Oncology. According to data from OpenAlex, George J. Hutton has authored 46 papers receiving a total of 865 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pathology and Forensic Medicine, 11 papers in Neurology and 10 papers in Oncology. Recurrent topics in George J. Hutton's work include Multiple Sclerosis Research Studies (34 papers), Peripheral Neuropathies and Disorders (9 papers) and Polyomavirus and related diseases (8 papers). George J. Hutton is often cited by papers focused on Multiple Sclerosis Research Studies (34 papers), Peripheral Neuropathies and Disorders (9 papers) and Polyomavirus and related diseases (8 papers). George J. Hutton collaborates with scholars based in United States, Canada and United Kingdom. George J. Hutton's co-authors include Fernando X. Cuascut, Víctor M. Rivera, Jian Hong, Jade S. Schiffman, Timothy Lotze, Jill V. Hunter, Jennifer L. Northrop, Jingwu Zhang, Ying C. Q. Zang and Jingwu Z. Zhang and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Neurology.

In The Last Decade

George J. Hutton

43 papers receiving 846 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
George J. Hutton United States 14 619 213 201 188 133 46 865
T. Arbizu Spain 15 563 0.9× 216 1.0× 154 0.8× 161 0.9× 165 1.2× 28 745
Isabel Boscá Spain 17 547 0.9× 242 1.1× 111 0.6× 163 0.9× 140 1.1× 26 693
Francisco Coret Spain 18 611 1.0× 332 1.6× 129 0.6× 175 0.9× 156 1.2× 36 762
Aurora Zanghì Italy 16 462 0.7× 169 0.8× 132 0.7× 174 0.9× 117 0.9× 50 648
Alexander Musallam United States 15 710 1.1× 245 1.2× 179 0.9× 117 0.6× 186 1.4× 21 1.0k
Jean‐Christophe Ouallet France 16 741 1.2× 324 1.5× 240 1.2× 107 0.6× 185 1.4× 44 1.0k
M. Cossburn United Kingdom 10 495 0.8× 241 1.1× 174 0.9× 120 0.6× 150 1.1× 17 687
Luciana Midaglia Spain 16 687 1.1× 326 1.5× 101 0.5× 113 0.6× 178 1.3× 44 892
Becky Parks United States 17 680 1.1× 348 1.6× 319 1.6× 201 1.1× 167 1.3× 31 1.2k
Paul O’Connor Canada 11 926 1.5× 329 1.5× 220 1.1× 284 1.5× 294 2.2× 22 1.1k

Countries citing papers authored by George J. Hutton

Since Specialization
Citations

This map shows the geographic impact of George J. Hutton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by George J. Hutton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites George J. Hutton more than expected).

Fields of papers citing papers by George J. Hutton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by George J. Hutton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by George J. Hutton. The network helps show where George J. Hutton may publish in the future.

Co-authorship network of co-authors of George J. Hutton

This figure shows the co-authorship network connecting the top 25 collaborators of George J. Hutton. A scholar is included among the top collaborators of George J. Hutton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with George J. Hutton. George J. Hutton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Jieni, George J. Hutton, & Rajender R. Aparasu. (2025). Prevalence of multiple sclerosis and disease-modifying therapy use in older adults in the United States, 2011–2021. Multiple Sclerosis Journal. 31(13). 1595–1599. 1 indexed citations
2.
Hutton, George J., et al.. (2024). Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis. Multiple Sclerosis and Related Disorders. 91. 105896–105896.
3.
Hutton, George J., et al.. (2024). Infection Risk Associated with High‐Efficacy Disease‐Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. Clinical Pharmacology & Therapeutics. 117(2). 561–569. 1 indexed citations
4.
Rempe, Torge, et al.. (2024). Frequency, characteristics, predictors and treatment of relapsing myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD). Multiple Sclerosis and Related Disorders. 87. 105672–105672. 2 indexed citations
5.
6.
Hutton, George J., et al.. (2023). Comparative adherence trajectories of oral disease‐modifying agents in multiple sclerosis. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 43(6). 473–484. 1 indexed citations
7.
Pérez, Carlos A., et al.. (2023). Health Disparities in Multiple Sclerosis among Hispanic and Black Populations in the United States. Biomedicines. 11(4). 1227–1227. 8 indexed citations
8.
Huang, Yinan, et al.. (2023). Assessing treatment switch among patients with multiple sclerosis: A machine learning approach. SHILAP Revista de lepidopterología. 11. 100307–100307. 4 indexed citations
9.
Hutton, George J., et al.. (2022). Health-related quality of life of patients with multiple sclerosis: Analysis of ten years of national data. Multiple Sclerosis and Related Disorders. 66. 104019–104019. 7 indexed citations
10.
Hutton, George J., et al.. (2022). FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS. Multiple Sclerosis and Related Disorders. 60. 103703–103703. 1 indexed citations
11.
Hutton, George J., et al.. (2021). Comparative treatment effectiveness of oral fingolimod and conventional injectable disease‐modifying agents in multiple sclerosis. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 41(5). 440–450. 2 indexed citations
12.
Nakamura, Kunio, Sridar Narayanan, Robert A. Brown, et al.. (2021). Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders. 54. 103149–103149. 4 indexed citations
13.
Hutton, George J., et al.. (2020). Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records. Multiple Sclerosis and Related Disorders. 45. 102334–102334. 9 indexed citations
14.
Hutton, George J., et al.. (2020). <p>Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis</p>. Patient Preference and Adherence. Volume 14. 2187–2199. 12 indexed citations
15.
Paranjpe, Rutugandha, et al.. (2020). Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data. Research in Social and Administrative Pharmacy. 16(12). 1670–1676. 5 indexed citations
16.
Yeo, Crystal Jing Jing, George J. Hutton, & Steve H. Fung. (2018). Advanced neuroimaging in Balo's concentric sclerosis: MRI, MRS, DTI, and ASL perfusion imaging over 1 year. Radiology Case Reports. 13(5). 1030–1035. 8 indexed citations
17.
Schürmann, Paul, et al.. (2013). Abnormal rhythms in patients without known cardiac disease after a first dose of fingolimod. Multiple Sclerosis and Related Disorders. 3(3). 408–412. 5 indexed citations
18.
Hutton, George J., et al.. (2011). The Role of Postpartum Intravenous Corticosteroids in the Prevention of Relapses in Multiple Sclerosis. International Journal of MS Care. 13(2). 91–93. 7 indexed citations
19.
20.
Hong, Jian & George J. Hutton. (2010). Regulatory Effects of Interferon-β on Osteopontin and Interleukin-17 Expression in Multiple Sclerosis. Journal of Interferon & Cytokine Research. 30(10). 751–757. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T. Arbizu Breakdown of academic impact, for papers by Isabel Boscá Breakdown of academic impact, for papers by Francisco Coret Breakdown of academic impact, for papers by Aurora Zanghì Breakdown of academic impact, for papers by Alexander Musallam Breakdown of academic impact, for papers by Jean‐Christophe Ouallet Breakdown of academic impact, for papers by M. Cossburn Breakdown of academic impact, for papers by Luciana Midaglia Breakdown of academic impact, for papers by Becky Parks Breakdown of academic impact, for papers by Paul O’Connor
Rankless by CCL
2026